在COVID-19患者中与雷梅西维尔相关的心脏不良影响:一项病例对照研究
Fatemah Abedipour1,2, Hossein Hadavand Mirzaei1, Hossein Ansari3
1Department of Infectious Disease, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
在COVID-19患者中使用雷梅西维尔与心血管问题有关,特别是鼻肌梗塞. 男人,老年人和吸烟者表现出更高的并发症率,胆红素和ALKP水平发生显著变化.
科学领域:
- 心脏病学 心脏病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 报告显示,雷梅西维尔的严重副作用包括心血管并发症.
- 用雷姆迪西维尔治疗COVID-19需要了解其心脏安全性.
研究的目的:
- 为了确定Remdesivir在COVID-19患者的不良心血管影响.
- 为了确定与Remdesivir诱导的心血管并发症相关的因素.
主要方法:
- 接受雷梅西维尔的患者被分为有心血管并发症和没有心血管并发症的组.
- 检查了医疗记录,以评估各种因素与心血管不良事件之间的关系.
主要成果:
- 心血管并发症在男性和老年患者中明显更为普遍.
- 吸烟与心血管并发症的增加有显著的关联.
- 在治疗前和治疗后两组之间观察到比利鲁宾和酸酶 (ALKP) 的平均变化有显著差异.
结论:
- 鼻肌梗塞是最常见的并发症,主要影响男性.
- 高龄和吸烟是Remdesivir相关心血管并发症的危险因素.
- 胆红素和ALKP水平的变化可能表明,在接受Remdesivir治疗的患者中存在心脏风险.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
